Evaluating the risk of drug-drug interactions with pharmacokinetic boosters: the case of ritonavir-enhanced nirmatrelvir to prevent severe COVID-19.

Details

Ressource 1Download: Girardin_CMI_2022.pdf (220.67 [Ko])
State: Public
Version: author
License: Not specified
Serval ID
serval:BIB_30CD844F1841
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Evaluating the risk of drug-drug interactions with pharmacokinetic boosters: the case of ritonavir-enhanced nirmatrelvir to prevent severe COVID-19.
Journal
Clinical microbiology and infection
Author(s)
Girardin F., Manuel O., Marzolini C., Buclin T.
ISSN
1469-0691 (Electronic)
ISSN-L
1198-743X
Publication state
In Press
Peer-reviewed
Oui
Language
english
Notes
Publication types: Journal Article
Publication Status: aheadofprint
Keywords
COVID-19, antivirals, drug safety, drug-drug interactions, nirmatrelvir, ritonavir
Pubmed
Open Access
Yes
Create date
11/04/2022 9:17
Last modification date
21/05/2022 7:08
Usage data